(Q45766668)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Ju Hyun Shim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Joo Ho Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Young-Hwa Chung

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Jeong A Kim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Danbi Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Han Chu Lee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Eun-Soon Shin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Byung Ik Kim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Si Hyun Bae

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Kwang Cheol Koh

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Neung-Hwa Park

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

26 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

136-142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22736425%20AND%20SRC:MED&resulttype=core&format=json

Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Effect of selenium-enriched malt on VEGF and several relevant angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

COX-2 gene promoter haplotypes and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-α, and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021

Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021

Hand-foot and stump syndrome to sorafenib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021

Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021

How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021

Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27705

7 January 2021